Peptide Rules: Why Your State Still Matters After the Federal Notice (2026) On Oct 30, 2026 a federal HHS notice on pharmacy-made peptides was published. The same day, Utah's licensing division said it will use similar limited discretion only when every federal condition is met. The Alliance for Pharmacy Compounding notes that federal enforcement discretion does not bind the states. The notice is interim and not FDA approval, and human evidence for most covered peptides is early. Three questions to ask: who reviews you, which licensed pharmacy fills it, and what your state allows. Education only; a licensed provider decides every treatment. Are peptide rules the same in every state? No. A federal notice sets the outline, but each state can set its own course. Utah, for example, said on Oct 30, 2026 it will follow the federal approach only when every condition is met. HOO Longevity in the United States connects you with a licensed provider who checks what applies where you live. Sources: commerce.utah.gov (state agency notice), 2026: https://commerce.utah.gov/2026/10/30/peptide-enforcement-discretion-policy/ Learn this with HOO Longevity Academy by Join HOO Health: research-backed lessons and a new reel, carousel and story every day, in your own brand. Free Academy Live class every Tuesday evening. joinhoohealth.com/academy Education only, not medical advice. Rx programs require an online visit with a licensed provider. Results vary. #longevity #peptidescience #healthyaging #Shorts #HOOLongevityAcademy #JoinHOOHealth